title: How to detour Treg cells in T cell-based antitumor immune therapy.
abstract: T cell-based antitumor immune therapy which occupies the boosting area of translational medicine research is capable of eradicating some kinds of tumors that are in late stages. However, the effectiveness of adoptive cell transfer treatment varies among the different clinical trials, while the safety of cells is still uncertain for some patients. All these phenomena provoke us to ask whether the instability of T cell-based antitumor immune therapy is due to immune modulation function of Treg cells in the tumor microenvironment and the peripheral circulation. Some successful Treg-targeting treatments in clinical trials provide the inspiration for subtle modulation of Treg cells in future cancer immunotherapies. We hypothesized that Treg cells may somehow sense the abundance of peripheral immune effector cells, and maintain the shifted tumor-bearing homeostasis of the immune system. Killer cells infused in adoptive cell transfer therapy may be monitored and spontaneously downregulated by Treg cells. Further studies are required to develop more effective combinations of immunotherapy with conventional chemo/radiotherapy in the modulation of immune-suppressive cells.
authors.affiliation: The Cancer Institute, Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
authors.forename: Shu
authors.initials: S
authors.lastname: Zheng
authors.forename: Yanwei
authors.initials: Y
authors.lastname: Shen
authors.forename: Yongmao
authors.initials: Y
authors.lastname: Song
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
keywords: Treg cells; adoptive cell transfer; cytokine induction; immune modulation; regulatory T lymphocytes; tumor immune tolerance
references.citation: Cancer Immunol Immunother. 2007 Jan;56(1):117-28
references.pmid: 16676181
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Cell. 2013 May 23;153(5):1025-35
references.pmid: 23706740
references.citation: J Clin Invest. 2005 Jul;115(7):1953-62
references.pmid: 16007258
references.citation: Cancer Res. 2008 Jun 1;68(11):4026-30
references.pmid: 18519658
references.citation: Nat Med. 2013 Jan;19(1):57-64
references.pmid: 23202296
references.citation: J Immunother. 2007 Nov-Dec;30(8):825-30
references.pmid: 18049334
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Mol Ther. 2008 Apr;16(4):782-90
references.pmid: 18362931
references.citation: CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35
references.pmid: 22576456
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: Clin Lymphoma. 2000 Sep;1(2):110-6; discussion 117
references.pmid: 11707818
references.citation: N Engl J Med. 1988 Dec 22;319(25):1676-80
references.pmid: 3264384
references.citation: World J Gastroenterol. 2012 Jul 7;18(25):3303-9
references.pmid: 22783056
references.citation: Blood. 2009 Oct 29;114(18):3793-802
references.pmid: 19724059
references.citation: J Exp Med. 1982 Aug 1;156(2):385-97
references.pmid: 6980254
references.citation: J Immunol. 2007 Apr 1;178(7):4051-61
references.pmid: 17371959
references.citation: J Immunol. 2009 May 15;182(10):6160-7
references.pmid: 19414769
references.citation: J Clin Oncol. 2001 Jan 15;19(2):376-88
references.pmid: 11208829
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7470-9
references.pmid: 16243821
references.citation: Cancer. 2006 Dec 15;107(12):2866-72
references.pmid: 17099880
references.citation: J Natl Cancer Inst. 1991 Jan 2;83(1):37-42
references.pmid: 1984515
references.citation: Blood. 2005 Apr 1;105(7):2862-8
references.pmid: 15591121
references.citation: J Immunol. 2011 Dec 1;187(11):6130-42
references.pmid: 22048768
references.citation: Clin Cancer Res. 2012 Dec 1;18(23):6497-508
references.pmid: 23032745
references.citation: Curr Opin Immunol. 2009 Apr;21(2):233-40
references.pmid: 19304471
references.citation: Blood. 2009 Jun 11;113(24):6120-7
references.pmid: 19202127
references.citation: Acta Med Scand Suppl. 1953;276:1-103
references.pmid: 13039964
references.citation: J Clin Immunol. 2007 May;27(3):317-26
references.pmid: 17468835
references.citation: Clin Lymphoma. 2002 Mar;2(4):222-8
references.pmid: 11970761
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5060-9
references.pmid: 17075125
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: Cancer Res. 2007 Aug 1;67(15):7477-86
references.pmid: 17671218
references.citation: Urol Oncol. 2006 Sep-Oct;24(5):419-24
references.pmid: 16962494
references.citation: Oncoimmunology. 2013 Jan 1;2(1):e22246
references.pmid: 23482454